XIENCE™ Family of Drug-Eluting Stents

The World's Leading Drug-Eluting Stents (DES), with Unparalleled Clinical Outcomes¹

Innovative Stent Design

XIENCE™ Stent is not like other DES—it is the DES proven to provide uncompromising clinical results during and far beyond the intervention, not only helping interventional cardiologists (ICs) achieve enduring and positive patient outcomes, but also enabling patients to experience improved quality of life.¹

XIENCE™ Stent is uniquely designed for exceptional performance1

XIENCE™ Stent is designed to deliver uncompromising clinical success based on a unique combination of stent design, fluoropolymer and drug.

Innovative Stent Design

  • Flexible stent and delivery system offers conformability to vessel anatomy2
  • Low metal-to-artery ratio reduces injury and/or inflammation3
  • Thin, well-apposable struts for rapid re-endothelialization, healing and reduced thrombogenicity4
XIENCE™ Stent design is the reason for its safety and uncompromising clinical results

Anti-Thrombotic Fluoropolymer

The XIENCE™ Stent is significantly more anti-thrombotic than other DES5 due to:

  • Less platelet adhesion
  • Less inflammation
  • Coating that is durable and flexible
The XIENCE™ Stent fluoropolymer is more anti-thrombotic than competitors' stents

Market-Leading Everolimus3

  • 20,000,000 implants worldwide
  • Most studied and used DES
  • Elution rate or everolimus matches restenosis cascade6
  • Low drug dose6,7
  • Broad therapeutic range6
Low doses of Everolimus, the market-leading drug for drug-eluting stents, enhance XIENCE™ Stent safety

Just as the stent design is critical to patient outcomes and quality of life, so are the polymer coatings and the drug elution profile.


  1. Zanchin C, et al. JACC Cardiovasc Interv. 2019;12(17):1665-1675. Serruys P, et al. N Engl J Med. 2010;363:136-146. Shiomi H, et al. JACC Cardiovasc Interv. 2019;12:637-647. Kufner S, et al. Circulation. 2019:139(3):325-333. Palmerini T, et al. Lancet. 2013;379:1393-1402. Bangalore S, et al. Circulation. 2012;125:2873-2891. Bangalore S, et al. Circ Cardiovasc Interv. 2013;6(6):378-390. Pilgrim T, et al. Lancet. 2014;384:2111-2122. Pilgrim T, et al. Lancet. 2018;392:737-746. Baron S, et al. J Am Coll Cardiol. 2017;70:3113-3122. Data on file at Abbott.
  2. Colombo A, et al. J Am Coll Cardiol. 2002;40:1021-1033.
  3. Data on file at Abbott. 20,000,000 implants number is based on data of DES implants through Q4 2022.
  4. Kolandaivelu K, et al. Circulation. 2011;123;1400-1409. Kastrati A, et al. Circulation. 2001;103;2816-2821.
  5. Jinnouchi H, et al. J Am Coll Cardiol. 2019;74(Suppl B): TCT-291.
  6. Perkins LEL, et al. J Interven Cardiol. 2009;22:S28-S40.
  7. Ding N, et al. J Interv Cardiol. 2009;22:S18-S27.
Manuals & Technical Resources

Manuals & Technical Resources

Order Cardiovascular Products

Cardiovascular Products

Customer Service

Customer Service

MAT-2010598 v2.0